PROF

Profound is a genuine commercial-stage medtech, not a shell: TULSA-PRO is FDA 510(k)-cleared, CE-marked and Health-Canada-approved for incision-free MRI-guided prostate ablation, and the numbers show a real ramp — FY2025 revenue of $16.1M grew 50.7% YoY (from $7.2M in FY2023 → $10.7M → $16.1M) at a healthy 70.8% gross margin. The balance sheet is clean on the debt side: liabilities/equity of just 0.17x, only $4.5M long-term debt, and $59.7M cash against $66.4M equity. That is the bull case, and it is not nothing.

The problem is that growth is being bought at a widening loss. Net loss deepened to -$42.6M (from -$27.8M), operating margin is -256%, and operating cash flow worsened 62.9% to -$38.2M — i.e. the company is burning cash faster than revenue is growing. Against $59.7M cash that is roughly 1.5 years of runway, so a dilutive raise is a near-certainty on a long horizon; shares already grew 20.8% in a single year, and the accumulated deficit sits at -$288M. R&D of $20.6M alone exceeds total revenue, so profitability is not on any near visible line. The MD&A confirms this is still a build-out story — 'primarily rely on our in-house sales and marketing capabilities... substantial build-up and commitment of resources' — and Risk Factors lead with 'history of operating losses,' 'capital intensive and requires significant investment,' single-source suppliers, and dependence on reimbursement/market acceptance of TULSA-PRO.